Taysha Gene Therapies, Inc. Variable Lease, Cost
Taysha Gene Therapies, Inc. (TSHA) reported Variable Lease, Cost of $242.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Taysha Gene Therapies, Inc. variable lease, cost for the quarter ending 2026-06-30 was $242.00K, a 39.80% decline year-over-year.
- Taysha Gene Therapies, Inc. variable lease, cost for the quarter ending 2026-03-31 was $290.00K, a 14.45% decline year-over-year.
- Taysha Gene Therapies, Inc. variable lease, cost for the quarter ending 2025-12-31 was $402.00K, a 98.03% increase year-over-year.
- Taysha Gene Therapies, Inc. variable lease, cost for the quarter ending 2025-09-30 was $407.00K, a 91.98% increase year-over-year.
- Taysha Gene Therapies, Inc. variable lease, cost for fiscal 2025 was $1.55M, a 91.12% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. variable lease, cost for fiscal 2024 was $811.00K, a 15.52% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. variable lease, cost for fiscal 2023 was $960.00K, a 112.39% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. variable lease, cost for fiscal 2022 was $452.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $242.00K 10-Q · filed 2026-08-11 | $532.00K 10-Q · filed 2026-08-11 | $934.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $290.00K 10-Q · filed 2026-05-06 | $692.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.10M derived: sum of 3 quarters · filed 2026-05-06 | $1.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $809.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.21M derived: sum of 3 quarters · filed 2026-08-11 | $1.55M 10-K · filed 2026-03-19 |
| 2025-09-30 | $407.00K 10-Q · filed 2025-11-04 | $809.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.15M 10-Q · filed 2025-11-04 | $1.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $402.00K 10-Q · filed 2026-08-11 | $741.00K 10-Q · filed 2026-08-11 | $944.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $339.00K 10-Q · filed 2026-05-06 | $542.00K derived: sum of 2 quarters · filed 2026-05-06 | $754.00K derived: sum of 3 quarters · filed 2026-05-06 | $952.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $415.00K derived: sum of 2 quarters · filed 2026-03-19 | $613.00K derived: sum of 3 quarters · filed 2026-03-19 | $811.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $212.00K 10-Q · filed 2025-11-04 | $410.00K derived: sum of 2 quarters · filed 2025-11-04 | $608.00K 10-Q · filed 2025-11-04 | $839.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $198.00K 10-Q · filed 2025-08-12 | $396.00K 10-Q · filed 2025-08-12 | $627.00K derived: sum of 3 quarters · filed 2025-08-12 | $870.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $198.00K 10-Q · filed 2025-05-15 | $429.00K derived: sum of 2 quarters · filed 2025-05-15 | $672.00K derived: sum of 3 quarters · filed 2025-05-15 | $915.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $474.00K derived: sum of 2 quarters · filed 2025-02-26 | $717.00K derived: sum of 3 quarters · filed 2025-02-26 | $960.00K 10-K · filed 2025-02-26 |
| 2023-09-30 | $243.00K 10-Q · filed 2024-11-13 | $486.00K derived: sum of 2 quarters · filed 2024-11-13 | $729.00K 10-Q · filed 2024-11-13 | $564.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $243.00K 10-Q · filed 2024-08-12 | $486.00K 10-Q · filed 2024-08-12 | $321.00K derived: sum of 3 quarters · filed 2024-08-12 | $550.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $243.00K 10-Q · filed 2024-05-14 | $78.00K derived: sum of 2 quarters · filed 2024-05-14 | $307.00K derived: sum of 3 quarters · filed 2024-05-14 | $501.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $64.00K derived: sum of 2 quarters · filed 2024-03-19 | $258.00K derived: sum of 3 quarters · filed 2024-03-19 | $452.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $229.00K 10-Q · filed 2023-11-14 | $423.00K derived: sum of 2 quarters · filed 2023-11-14 | $617.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $194.00K 10-Q · filed 2023-08-14 | $387.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $194.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |